Inmed Pharmaceuticals Inc (INM)

$4.95 +0.45 (10.00%)
Market Cap 3.26M
Revenue (ttm) 4.60M
Net Income (ttm) -7.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -166.96%
Debt to Equity Ratio 0.00
Volume 39,800
Avg Vol 34,448
Day's Range N/A - N/A
Shares Out 724,000.00
Stochastic %K 68%
Beta 0.23
Analysts Strong Buy
Price Target $45.00

Latest News on INM

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 4 weeks ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 4 weeks ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 2 months ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 2 months ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 2 months ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 2 months ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 2 months ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 3 months ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 3 months ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 3 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 4 months ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 5 months ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 5 months ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 5 months ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 6 months ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 7 months ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 8 months ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 9 months ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 9 months ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 10 months ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 10 months ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 1 year ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 1 year ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 1 year ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 1 year ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Nov 2, 2023, 8:00 AM EDT - 1 year ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 7:15 PM EDT - 1 year ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 1 year ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Oct 24, 2023, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

Sep 29, 2023, 1:21 PM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Sep 22, 2023, 6:15 PM EDT - 1 year ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:30 AM EDT - 1 year ago

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

Jul 21, 2023, 7:30 AM EDT - 1 year ago

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

InMed Provides Update on BayMedica Rare Cannabinoid Business

Jul 20, 2023, 7:30 AM EDT - 1 year ago

InMed Provides Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

Jun 22, 2023, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

Jun 1, 2023, 7:30 AM EDT - 1 year ago

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023, 5:00 PM EDT - 1 year ago

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023, 12:33 PM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Mar 28, 2023, 7:30 AM EDT - 1 year ago

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

InMed to Participate in Upcoming Investor Events

Mar 6, 2023, 6:00 PM EST - 2 years ago

InMed to Participate in Upcoming Investor Events

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

Feb 17, 2023, 5:00 PM EST - 2 years ago

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Submits Form 12b-25

Feb 9, 2023, 9:41 PM EST - 2 years ago

InMed Submits Form 12b-25

InMed Provides Business Update and Milestones for 2023

Jan 10, 2023, 7:30 AM EST - 2 years ago

InMed Provides Business Update and Milestones for 2023

InMed Announces Results of 2022 Annual General Meeting

Dec 15, 2022, 6:17 PM EST - 2 years ago

InMed Announces Results of 2022 Annual General Meeting

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

Dec 12, 2022, 6:47 PM EST - 2 years ago

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

Nov 21, 2022, 5:00 PM EST - 2 years ago

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

Nov 18, 2022, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Provides Update on Management Changes

Nov 17, 2022, 7:30 AM EST - 2 years ago

InMed Provides Update on Management Changes